Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 42.07 · gapped below the open, then crossed back over prior close. High/low 42.25 at 4:45 pm ET, 41.12 at 10:45 am ET.
Harmony Biosciences Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the year ended December 31, 2025, three customers accounted for 100% of gross product revenue; Caremark LLC accounted for 38% of gross product revenue; Accredo Health Group, Inc. accounted for 36% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 26% of gross product revenue.”
$330M relationship
basisHRMY fy2025 · closed 2025-12 $868M
FILING10-K0001104659-26-018859cik 0001802665
“For the year ended December 31, 2025, three customers accounted for 100% of gross product revenue; Caremark LLC accounted for 38% of gross product revenue; Accredo Health Group, Inc. accounted for 36% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 26% of gross product revenue.”
$313M relationship
basisHRMY fy2025 · closed 2025-12 $868M
FILING
“For the year ended December 31, 2025, three customers accounted for 100% of gross product revenue; Caremark LLC accounted for 38% of gross product revenue; Accredo Health Group, Inc. accounted for 36% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 26% of gross product revenue.”
$226M relationship
basisHRMY fy2025 · closed 2025-12 $868M
FILING
“Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization ("CDMO") manufactures our API.”
FILING10-K0001104659-26-018859cik 0001802665
“Interor S.A. manufactures our BF4 and BF6 intermediate and starting material used in the active pharmaceutical ingredient ("API").”
FILING10-K0001104659-26-018859cik 0001802665
“Patheon UK Limited and Patheon Pharmaceuticals, Inc., CDMOs owned by Thermo Fisher Scientific Inc., manufacture our finished product tablets.”
FILING10-K0001104659-26-018859cik 0001802665
“Patheon UK Limited and Patheon Pharmaceuticals, Inc., CDMOs owned by Thermo Fisher Scientific Inc., manufacture our finished product tablets.”
FILING10-K0001104659-26-018859cik 0001802665
“Pharma Packaging Solutions, LLC dba Tjoapack, LLC, fills unlabeled bottles and performs labeling and secondary packaging.”
FILING10-K0001104659-26-018859cik 0001802665
“Procos, S.p.A. operates as an alternate drug substance manufacturing site for WAKIX API.”
FILING10-K0001104659-26-018859cik 0001802665
“In October 2023, we acquired Zynerba Pharmaceuticals, Inc. ("Zynerba"), adding global rights to develop, manufacture and commercialize ZYN002, which is a pharmaceutically manufactured 100% synthetic, patent protected permeation enhanced cannabidiol gel for transdermal delivery.”
FILING10-K0001104659-26-018859cik 0001802665
“Cardinal Health, Inc. is our third-party logistics provider and manages reverse distribution, pharmaceutical returns and product recall, if needed.”
FILING10-K0001104659-26-018859cik 0001802665
“Patheon UK Limited and Patheon Pharmaceuticals, Inc., CDMOs owned by Thermo Fisher Scientific Inc., manufacture our finished product tablets.”
FILING10-K0001104659-26-018859cik 0001802665
“In July 2017, we entered into a License Agreement (as amended, the "2017 LCA") with Bioprojet Société Civile de Recherche ("Bioprojet") whereby we acquired the exclusive right to commercialize the pharmaceutical compound pitolisant.”
FILING10-K0001104659-26-018859cik 0001802665
“In June 2025, we entered into a research collaboration, option and license agreement (the "CiRC Agreement") with a related party, CiRC Biosciences, Inc. ("CiRC").”
FILING10-K0001104659-26-018859cik 0001802665
“In August 2021, we acquired HBS-102, a Melanin-concentrating hormone receptor type 1 (MCHR1) antagonist previously developed as CSTI-100/ALB-127258(a)/ALB-127258 (the "Compound"), along with intellectual property and other assets related to the development, manufacture, and commercialization of the Compound from ConSynance Therapeutics, Inc.”
FILING10-K0001104659-26-018859cik 0001802665
“Under the Sublicense, we obtained the exclusive right to develop, manufacture and commercialize BP1.15205 in the United States and Latin American territories, which are rights originally licensed from Teijin Pharma, the innovator of BP1.15205.”
FILING10-K0001104659-26-018859cik 0001802665
Watchlist prices, news filtered to it, and its next report on your desk.
Harmony Biosciences Holdings, Inc. has 13 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Harmony Biosciences Holdings, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
HRMY (Harmony Biosciences Holdings, Inc.) has 13 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TMO +4.46%, in healthcare.